Abstract 107P
Background
The WHO reported breast cancer incidence in the Philippines to be 33,079 in 2022 - among the highest in Asia. Data by the Philippine Cancer Society and Department of Health Rizal Cancer Registry in 2009 included 1,615 breast cancer patients and noted an increase in incidence from 1980 to 2002. This retrospective study aims to describe and analyze clinicopathologic and treatment data of Filipino breast cancer patients in a tertiary hospital. This is the largest pooled data in the Philippines on breast cancer demographics.
Methods
Patients diagnosed with invasive breast cancer in St. Luke’s Medical Center from 2009 to 2020 were included. Patients diagnosed with pre-malignant breast histopathologies and double primaries were excluded. Study was approved by the Ethics Review Committee (Ref No. SL-19157).
Results
A total of 5,462 breast cancer patients were included. Majority were late perimenopausal (50-59 yo, 30.06%), menopausal (60-69 yo, 23.03%), and premenopausal (below 44 yo, 19.28%,) at time of diagnosis. Patients were diagnosed with stage II (N = 1,816, 47.24%), followed by stage I (N = 943, 24%), and stage III (N = 662, 17%). Sixty four percent (N = 1,498) were node negative while 46% (N = 1,300) were node positive. For de novo metastatic patients, 14.6% metastasized to the bone while visceral sites include lung (16.6%), liver (11.5%) and brain (7.45%). Luminal her2- (48.9%) was the most common subtype followed by non-luminal her2+ (15.6%) and triple negative (6.7%). Ninety four percent (N = 4116) underwent modified radical mastectomy (MRM) while 5% (N = 223) had breast conserving surgery (BCS). Eight hundred patients (19%) received neoadjuvant treatment while 2,246 patients (54%) had adjuvant treatment. Patients with adjuvant radiation was 1,399 (25.6%).
Conclusions
Compared to middle-high income countries, our data suggests that MRM is the preferred surgical technique over BCS. Majority of patients in the study are luminal her2-. However, only 54% received adjuvant treatment. Further research on risk factors or reasons for not receiving treatment as well as the outcomes of this patient cohort is needed to shed light on this cancer care gap.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.